Inovio » About Us » Leadership » Biography

"Immunization ranks among the most important health advances of the 20th century. With the exception of safe drinking water, vaccinology has more effectively reduced mortality than any other modality."

"Extraordinary advances in biotechnology make DNA vaccines the most promising area of vaccinology."

Advances in DNA vaccines
Nurse Practitioner
James Mark Simmerman
Jan 2002

"I have stated in public seminars that, in my opinion, electroporation is the gold standard for DNA vaccine delivery, giving us the best result in terms of immunogenicity of DNA vaccines."

George N. Pavlakis, MD, PhD
Chief
Human Retrovirus Section, Vaccine Branch
National Cancer Institute

home » about us » leadership » tazdin esmail

Biography

Tazdin Esmail
Retired biotechnology industry executive (Protox)

TAZDIN ESMAIL has been a director of Inovio since August 2000. In 2006, Mr. Esmail retired from his roles as president, chief executive officer and director of Protox Therapeutics Inc., a company developing targeted proteins for the treatment of cancer. He was the founder and former president, chief executive officer, director, and chairman of the board of Forbes Medi-Tech Inc. He is a former vice president of operations of QLT Inc., a TSX/NASDAQ listed biotechnology company, and a former director of pharmaceutical operations for the multinational pharmaceutical company, American Cyanamid (now Wyeth), where he managed the company's oncology and hospital products division. He has raised approximately $90 million through private placements, public offerings and strategic alliances, and has extensive experience in growing companies from the start-up stage to public markets.